Immunohistochemical and biochemical expression patterns of TTF-1, RAGE, GLUT-1 and SOX2 in HCV-associated hepatocellular carcinomas
dc.Affiliation | October University for modern sciences and Arts (MSA) | |
dc.contributor.author | Aboushousha T. | |
dc.contributor.author | Mamdouh S. | |
dc.contributor.author | Hamdy H. | |
dc.contributor.author | Helal N. | |
dc.contributor.author | Khorshed F. | |
dc.contributor.author | Safwat G. | |
dc.contributor.author | Seleem M. | |
dc.contributor.other | Pathology Departmenty | |
dc.contributor.other | ||
dc.contributor.other | Giza | |
dc.contributor.other | Egypt; Biochemistry Departmenty | |
dc.contributor.other | ||
dc.contributor.other | Giza | |
dc.contributor.other | Egypt; Surgical Department | |
dc.contributor.other | Theodor Bilharz Research Institutey | |
dc.contributor.other | ||
dc.contributor.other | Giza | |
dc.contributor.other | Egypt; Faculty of Biotechnology | |
dc.contributor.other | ||
dc.contributor.other | Giza | |
dc.contributor.other | Egypt; National Hepatology and Tropical Medicine Research Institute | |
dc.contributor.other | Cairo | |
dc.contributor.other | Egypt | |
dc.date.accessioned | 2020-01-09T20:41:03Z | |
dc.date.available | 2020-01-09T20:41:03Z | |
dc.date.issued | 2018 | |
dc.description | Scopus | |
dc.description | MSA Google Scholar | |
dc.description.abstract | Objective: To investigate the expression of TTF-1, RAGE, GLUT1 and SOX2 in HCV-associated HCCs and in surrounding non-tumorous liver tissue. Material and Methods: Tissue material from partial hepatectomy cases for HCC along with corresponding serum samples and 30 control serum samples from healthy volunteers were studied. Biopsies were classified into: non-tumor hepatic tissue (36 sections); HCC (33 sections) and liver cell dysplasia (LCD) (15 sections). All cases were positive for HCV. Immunohistochemistry (IHC), gene extraction and quantitative real-time reverse-transcription assays (qRT-PCR) were applied. Results: By IHC, LCD and HCC showed significantly high percentages of positive cases with all markers. SOX2 showed significant increase with higher HCC grades, while RAGE demonstrated an inverse relation and GLUT-1 and TTF-1 lacked any correlation. In nontumorous-HCV tissue, we found significantly high TTF-1, low RAGE and negative SOX2 expression. RAGE, GLUT-1 and SOX2 show non-significant elevation positivity in high grade HCV compared to low grade lesions. TTF-1, RAGE and SOX2 exhibited low expression in cirrhosis compared to fibrosis. Biochemical studies on serum and tissue extracts revealed significant down-regulation of RAGE, GLUT-1 and SOX2 genes, as well as significant up-regulation of the TTF-1 gene in HCC cases compared to controls. All studied genes show significant correlation with HCC grade. In non-tumor tissue, only TTF-1 gene expression had a significant correlation with the fibrosis score. Conclusion: Higher expression of TTF-1, RAGE, GLUT-1 and SOX2 in HCC and dysplasia compared to non-tumor tissues indicates up-regulation of these markers as early events during the development of HCV-associated HCC. | en_US |
dc.identifier.doi | https://doi.org/10.22034/APJCP.2018.19.1.219 | |
dc.identifier.doi | PubMedID29373917 | |
dc.identifier.issn | 15137368 | |
dc.identifier.other | https://doi.org/10.22034/APJCP.2018.19.1.219 | |
dc.identifier.other | PubMedID29373917 | |
dc.identifier.uri | https://t.ly/lWWGB | |
dc.language.iso | English | en_US |
dc.publisher | Asian Pacific Organization for Cancer Prevention | en_US |
dc.relation.ispartofseries | Asian Pacific Journal of Cancer Prevention | |
dc.relation.ispartofseries | 19 | |
dc.subject | GLUT1 | en_US |
dc.subject | HCC | en_US |
dc.subject | HCV | en_US |
dc.subject | IHC | en_US |
dc.subject | RAGE | en_US |
dc.subject | SOX2 | en_US |
dc.subject | TTF1 | en_US |
dc.title | Immunohistochemical and biochemical expression patterns of TTF-1, RAGE, GLUT-1 and SOX2 in HCV-associated hepatocellular carcinomas | en_US |
dc.type | Article | en_US |
dcterms.isReferencedBy | Agoff, S.N., Lamps, L.W., Philip, A.T., Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors (2000) Mod Pathol, 13, pp. 238-242; Airley, R.E., Mobasheri, A., Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics (2007) Chemotherapy, 53, pp. 233-256; Amann, T., Maegdefrau, U., Hartmann, A., GLUT-1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis (2009) Am J Pathol, 174, pp. 1544-1552; Basu-Roy, U., Seo, E., Ramanathapuram, L., Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas (2012) Oncogene, 31, pp. 2270-2282; Blechacz, B., Mishra, L., Hepatocellular carcinoma biology (2013) Recent Results Cancer Res, 190, pp. 1-20; Bosman, F.T., Carneiro, F., Hruban, R.H., Theise, N.D., Tumours of the liver and intrahepatic bile ducts (2010) In 'pathology and genetics of tumors of the digestive system', pp. 205-216. , Eds International Agency for Research on Cancer, Lyon; Boyer, L.A., Lee, T.I., Cole, M.F., Core transcriptional regulatory circuitry in human embryonic stem cells (2005) Cell, 122, pp. 947-956; Cao, Q., Liu, F., Xiao, P., Cytoplasmic staining of TTF-1 antibody in the diagnosis of hepatocellular carcinoma: study on 299 cases using tissue microarray (2011) ISRN Pathol, 7; Chen, S., Mandavilli, S., Mandich, D., Perkins, M.L., Cartun, R.W., Value of thyroid transcription factor (TTF-1) and anti-hepatocyte monoclonal antibodies in differentiating hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA) in liver (2001) Mod Pathol, 14, p. 1138; Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., Maity, A., Regulation of glut-1 mRNA by hypoxia inducible factor-1 (2001) J Biol Chem, 276, pp. 9519-9525; Comp�rat, E., Zhang, F., Perrotin, C., Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin (2005) Mod Pathol, 18, pp. 1371-1376; Czech, B., Valletta, D., Saugspier, M., Effect of increased glucose transporter 1 (GLUT-1) expression in activated hepatic stellate cells (2013) Z Gastroenterol, 51, pp. 1-10; Czech, B., Valletta, D., M�ller, M., Bosserhoff, A., Hellerbrand, C., Expression and function of glucose transporter 1 (GLUT-1) expression in activated hepatic stellate cells (2014) Z Gastroenterol, 52, pp. 1-15; El-Tayeha, S.F., Husseina, T.D., El-Houseini, M.E., Serological biomarkers of hepatocellular carcinoma in Egyptian patients (2012) Dis Markers, 32, pp. 255-263; Fang, X., Yu, W., Li, L., ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers (2010) OMICS, 14, pp. 369-384; Fang, X., Yoon, J.G., Li, L., The SOX2 response program in glioblastoma multiforme: an integrated ChIPseq, expression microarray, and microRNA analysis (2011) BMC Genomics, 12, pp. 11-28; Folpe, A.L., Gown, M.D., Lamps, L.W., Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors (1999) Mod Pathol, 12, pp. 5-8; Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma (2012) Lancet, 379, pp. 1245-1255; Gatenby, R.A., Smallbone, K., Maini, P.K., Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer (2007) Br J Cancer, 97, pp. 646-653; Gokden, M., Shinde, A., Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver (2005) Diag Cytopathol, 33, pp. 166-172; Gomaa, A.I., Hashim, M.S., Waked, I., Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt (2014) PLoS One, 9; Han, X., Fang, X., Lou, X., Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients (2012) PLoS One, 7; Hiwatashi, K., Ueno, S., Abeyama, K., A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC (2007) Ann Surg Oncol, 15, pp. 923-933; Huang, P., Qiu, J., Li, B., Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy (2011) Clin Biochem, 44, pp. 582-589; Ito, R., Ishii, Y., Wakiyama, S., Prognostic significance of receptor for advanced glycation end products expression in hepatocellular carcinoma after hepatectomy (2014) J Surg Res, 192, pp. 503-508; Kang, S.S., Chun, Y.K., Hur, M.H., Clinical significance of glucose transporter 1 (GLUT-1) expression in human breast carcinoma (2002) Jpn J Cancer Res, 93, pp. 1123-1128; Kim, W.S., Kim, Y.Y., Jang, S.J., Kimm, K., Jung, M.H., Glucose transporter 1 (GLUT-1) expression is associated with intestinal type of gastric carcinoma (2000) J Korean Med Sci, 15, pp. 420-424; Krzeslak, A., Wojcik-Krowiranda, K., Forma, E., Expression of GLUT-1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers (2012) Pathol Oncol Res, 18, pp. 721-728; Lei, J.Y., Bourne, P.A., diSant'Agnese, P.A., Huang, J., Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver (2006) Am J Clin Pathol, 125, pp. 519-525; Li, X.L., Eishi, Y., Bai, Y.Q., Expression of the SRYrelated HMG box protein SOX2 in human gastric carcinoma (2004) Int J Oncol, 24, pp. 257-263; Mano, Y., Ishima, S., Kubo, Y., Correlation between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma (2014) Am J Clin Pathol, 142, pp. 391-397; Medina, R.A., Owen, G.I., Glucose transporters: expression, regulation and cancer (2002) Biol Res, 35, pp. 9-26; (2015) Egypt Health Issues Survey 2015, , Cairo, Egypt and Rockville, Maryland, USA: Ministry of Health and Population and ICF International; Mokhtar, N., Gouda, I., Adel, I., Malignant digestive system tumors (2007) In Cancer pathology registry 2003-2004 and time trend analysis, pp. 55-67. , Eds Mokhtar N, Gouda I, Adel I. Elsheraa Press, Cairo, Egypt; Nedic, O., Rattan, S.I.S., Grune, T., Trougakos, I.P., Molecular effects of advanced glycation end products on cell signaling pathways, ageing and pathophysiology (2013) Free Radic Res, 47, pp. 28-38; Poynard, T., Ratziu, V., Benmanov, Y., Fibrosis in patients with hepatitis c: detection and significance: detection and significance (2000) Semin Liver Dis, 20, pp. 47-55; Pusterla, T., N�meth, J., Stein, I., Receptor for advanced glycation end products (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice (2013) Hepatology, 58, pp. 363-373; Rodriguez-Pinilla, S.M., Sarrio, D., Moreno-Bueno, G., Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer (2007) Mod Pathol, 20, pp. 474-481; Sanada, Y., Yoshida, K., Ohara, M., Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components (2006) Pancreas, 32, pp. 164-170; Shaker, M.K., Abdella, H.M., Khalifa, M.O., Dorry, A.K.E., Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases (2013) Liver Int, 33, pp. 1601-1606; Sherman, M., Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis (2010) Semin Liver Dis, 30, pp. 3-16; Siegel, R., Naishadham, D., Jemal, A., Cancer statistics (2012) CA Cancer J Clin, 62, pp. 10-294; Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma (2012) Lancet, 379, pp. 1245-1255; Smith, T.A., Facilitative glucose transporter expression in human cancer tissue (1999) Br J Biomed Sci, 56, pp. 285-292; Sun, C., Sun, L., Li, Y., Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug (2013) Med Oncol, 30, pp. 503-512; Vlassara, H., Brownlee, M., Cerami, A., Advanced non-enzymatic tissue glycosylation: biochemical basis of late diabetic complications (1989) In diabetes mellitus: pathophysiology and therapy, pp. 209-217. , Eds Creutzfeldt W, Lef�bvre PJ. Springer, Berlin, Heidelberg; Waghray, A., Murali, A.R., Menon, K.N., Hepatocellular carcinoma: From diagnosis to treatment (2015) World J hepatol, 7, pp. 1020-1029; Wieczorek, T.J., Pinkus, J.L., Glickman, J.N., Pinkus, G.S., Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma (2002) Am J Clin Pathol, 118, pp. 911-921; Xu, X.C., Abuduhadeer, X., Zhang, W.B., Knockdown of RAGE inhibits growth and invasion of gastric cancer Cells (2013) Eur J Histochem, 29, pp. 240-246; Yamagishi, S., Matsui, T., Role of receptor for advanced glycation end products (RAGE) in liver disease (2015) Eur J Med Res, 20, pp. 15-22; Yilmaz, Y., Onen, H.I., Alp, E., Menevse, S., Real-time PCR for gene expression analysis (2012) In biochemistry, genetics and molecular biology "Polymerase chain reaction", pp. 229-254. , http://cdn.intechopen.com/pdfs-wm/37270.pdf, Eds Hernandez-Rodriguez P and Gomez AP, In Tech publisher, Rijeka, Croatia, [cit. 2014-07-10]; Yin, X., Li, Y., Jin, J., The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma (2013) Oncol Lett, 5, pp. 1155-1162; Yu, J., Vodyanik, M.A., Smuga-Otto, K., Induced pluripotent stem cell lines derived from human somatic cells (2007) Science, 318, pp. 1917-1920; Zhao, X., Sun, B., Sun, D., Slug promotes hepatocellular cancer cell progression by increasing sox2 and nanog expression (2015) Oncol Rep, 33, pp. 149-156 | |
dcterms.source | Scopus |